6.7
Agonistas Adrenérgicos: Agentes de Ação Mista
Os agonistas adrenérgicos de ação mista, como a efedrina e a pseudoefedrina, afetam diretamente e indiretamente os receptores adrenérgicos. Esses agen…
Os agonistas adrenérgicos de ação mista atuam diretamente estimulando os adrenoceptores e indiretamente liberando catecolaminas armazenadas dos terminais nervosos.
Ao contrário das catecolaminas endógenas, os agonistas de ação mista não possuem uma porção catecol, tornando-os substratos pobres para metabolizar enzimas, aumentando sua duração de ação.
Tanto a efedrina quanto a pseudoefedrina exibem excelente biodisponibilidade oral e penetração no SNC, mas são menos potentes que as catecolaminas.
A efedrina - isolada da planta Ephedra - tem sido usada como um simpatomimético ativo por via oral para o tratamento da asma.
Como a efedrina causa estimulação cardíaca e vasoconstrição, ela é usada para tratar a hipotensão induzida pela anestesia. No entanto, é um broncodilatador menos potente que a isoprenalina ou a adrenalina.
Além disso, seus efeitos estimulatórios centrais são responsáveis por seu abuso como intensificador de desempenho.
A pseudoefedrina - um isômero de efedrina com ação mais indireta - é eficaz por via oral e tem menos efeitos no SNC. É usado principalmente como descongestionante.
Como é comumente usado como precursor na produção ilegal de metanfetamina, sua venda é estritamente regulamentada.
View the full transcript and gain access to JoVE Core videos
Q1: How do mixed-acting adrenergic agonists differ from direct-acting agents?
Mixed-acting adrenergic agonists both stimulate adrenoceptors directly and indirectly release stored catecholamines from nerve terminals, amplifying the adrenergic response. Direct-acting agents only bind to receptors. Mixed-acting agents like ephedrine and pseudoephedrine lack a catechol moiety, making them resistant to metabolic degradation and extending their duration of action compared to endogenous catecholamines.
Q2: Why do ephedrine and pseudoephedrine have better oral bioavailability than catecholamines?
Ephedrine and pseudoephedrine lack a catechol moiety, which makes them poor substrates for metabolizing enzymes. This structural difference prevents rapid degradation, increasing their oral bioavailability and allowing them to reach systemic circulation effectively. Their lipophilicity also enhances absorption and CNS penetration, though they remain less potent than endogenous catecholamines.
Q3: What are the main clinical uses of ephedrine?
Ephedrine is used orally as a sympathomimetic agent for treating asthma and managing anesthesia-induced hypotension due to its cardiac stimulation and vasoconstriction effects. However, it is a less potent bronchodilator than isoprenaline or adrenaline. Its central stimulatory effects have led to abuse as a performance enhancer, limiting its therapeutic application.
Q4: Why is pseudoephedrine primarily used as a decongestant rather than for asthma?
Pseudoephedrine, an ephedrine isomer with predominantly indirect action, is orally effective with fewer central nervous system effects than ephedrine. These reduced CNS effects make it suitable for nasal decongestant use without significant stimulatory side effects. Its indirect mechanism of action and safety profile favor its use for congestion relief over asthma treatment.
Q5: How does prior catecholamine depletion affect mixed-acting agonist response?
Mixed-acting adrenergic agonists depend on releasing stored neurotransmitters for their indirect effects. Prior treatment with catecholamine-depleting agents like guanethidine or reserpine significantly reduces the agonist response by eliminating available stored catecholamines. This demonstrates the importance of the indirect mechanism in mixed-acting agent efficacy.
Q6: Why is pseudoephedrine's sale strictly regulated?
Pseudoephedrine is commonly used as a precursor in illegal methamphetamine production. Due to this abuse potential, its sale is strictly regulated to prevent diversion for illicit drug synthesis. Despite its legitimate therapeutic use as a decongestant, regulatory restrictions limit its availability and distribution.
Q7: What structural feature allows mixed-acting agonists to resist enzymatic degradation?
Mixed-acting adrenergic agonists like ephedrine and pseudoephedrine lack a catechol moiety present in endogenous catecholamines. This absence makes them poor substrates for metabolizing enzymes, preventing rapid degradation and increasing their duration of action. This structural modification is key to their extended therapeutic effect compared to natural catecholamines.